{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T03:26:43Z","timestamp":1791084403365,"version":"4.1.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,10,4]],"date-time":"2011-10-04T00:00:00Z","timestamp":1317686400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mol Med"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.2119\/molmed.2011.00164","type":"journal-article","created":{"date-parts":[[2012,2,10]],"date-time":"2012-02-10T20:29:10Z","timestamp":1328905750000},"page":"19-28","source":"Crossref","is-referenced-by-count":34,"title":["Sorafenib-Induced Apoptosis of Chronic Lymphocytic Leukemia Cells Is Associated with Downregulation of RAF and Myeloid Cell Leukemia Sequence 1 (Mcl-1)"],"prefix":"10.1186","volume":"18","author":[{"given":"Jessie-F.","family":"Fecteau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ila S.","family":"Bharati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"O\u2019Hayre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy M.","family":"Handel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Kipps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davorka","family":"Messmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,10,4]]},"reference":[{"key":"1801019_CR1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3322\/canjclin.49.1.8","volume":"49","author":"SH Landis","year":"1999","unstructured":"Landis SH, Murray T, Bolden S, Wingo PA. (1999) Cancer statistics, 1999. CA Cancer J. Clin. 49:8\u201331.","journal-title":"CA Cancer J. Clin."},{"key":"1801019_CR2","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.1002\/cncr.24329","volume":"115","author":"AM Tsimberidou","year":"2009","unstructured":"Tsimberidou AM, Keating MJ. (2009) Treatment of fludarabine-refractory chronic lymphocytic leukemia. Cancer. 115:2824\u201336.","journal-title":"Cancer"},{"key":"1801019_CR3","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/nrclinonc.2009.72","volume":"6","author":"L Pleyer","year":"2009","unstructured":"Pleyer L, Egle A, Hartmann TN, Greil R. (2009) Molecular and cellular mechanisms of CLL: novel therapeutic approaches. Nat. Rev. Clin. Oncol. 6:405\u201318.","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1801019_CR4","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1182\/blood-2004-12-4918","volume":"106","author":"M Burger","year":"2005","unstructured":"Burger M, et al. (2005) Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells. Blood. 106:1824\u201330.","journal-title":"Blood"},{"key":"1801019_CR5","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1046\/j.1365-2141.2003.04679.x","volume":"123","author":"F Caligaris-Cappio","year":"2003","unstructured":"Caligaris-Cappio F. (2003) Role of the microenvironment in chronic lymphocytic leukaemia. Br. J. Haematol. 123:380\u20138.","journal-title":"Br. J. Haematol."},{"key":"1801019_CR6","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1182\/blood.V99.3.1030","volume":"99","author":"N Tsukada","year":"2002","unstructured":"Tsukada N, Burger JA, Zvaifler NJ, Kipps TJ. (2002) Distinctive features of \u201cnurselike\u201d cells that differentiate in the context of chronic lymphocytic leukemia. Blood. 99:1030\u20137.","journal-title":"Blood"},{"key":"1801019_CR7","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1182\/blood-2010-04-282400","volume":"117","author":"D Messmer","year":"2011","unstructured":"Messmer D, et al. (2011) Chronic lymphocytic leukemia cells receive RAF-dependent survival signals in response to CXCL12 that are sensitive to inhibition by sorafenib. Blood. 117:882\u20139.","journal-title":"Blood"},{"key":"1801019_CR8","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1182\/blood-2004-03-0889","volume":"106","author":"M Nishio","year":"2005","unstructured":"Nishio M, et al. (2005) Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1alpha. Blood. 106:1012\u201320.","journal-title":"Blood"},{"key":"1801019_CR9","doi-asserted-by":"publisher","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","volume":"64","author":"SM Wilhelm","year":"2004","unstructured":"Wilhelm SM, et al. (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64:7099\u2013109.","journal-title":"Cancer Res."},{"key":"1801019_CR10","doi-asserted-by":"publisher","first-page":"35217","DOI":"10.1074\/jbc.M506551200","volume":"280","author":"M Rahmani","year":"2005","unstructured":"Rahmani M, Davis EM, Bauer C, Dent P, Grant S. (2005) Apoptosis induced by the kinase inhibitor BAY 43\u20139006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation. J. Biol. Chem. 280:35217\u201327.","journal-title":"J. Biol. Chem."},{"key":"1801019_CR11","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1358\/dot.2005.41.12.937959","volume":"41","author":"D Strumberg","year":"2005","unstructured":"Strumberg D. (2005) Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment. Drugs Today (Barc). 41:773\u201384.","journal-title":"Drugs Today (Barc)"},{"key":"1801019_CR12","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1517\/14656566.2010.496453","volume":"11","author":"R Iyer","year":"2010","unstructured":"Iyer R, Fetterly G, Lugade A, Thanavala Y. (2010) Sorafenib: a clinical and pharmacologic review. Expert Opin. Pharmacother. 11:1943\u201355.","journal-title":"Expert Opin. Pharmacother."},{"key":"1801019_CR13","first-page":"1163","volume-title":"Williams Hematology","author":"TJ Kipps","year":"2001","unstructured":"Kipps TJ. (2001) Chronic Lymphocytic Leukemia and Related Diseases. In: Williams Hematology. Beutler E, Lichtman MA, Coller BA, Kipps TJ, Seligsohn U (eds.). New York: McGraw-Hill, Medical Publishing Division, pp. 1163\u201394."},{"key":"1801019_CR14","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.3109\/10428194.2010.486089","volume":"51","author":"AM Tsimberidou","year":"2010","unstructured":"Tsimberidou AM, Keating MJ. (2010) Treatment of patients with fludarabine-refractory chronic lymphocytic leukemia: need for new treatment options. Leuk. Lymphoma. 51:1188\u201399.","journal-title":"Leuk. Lymphoma."},{"key":"1801019_CR15","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1182\/blood-2005-08-3182","volume":"107","author":"JA Burger","year":"2006","unstructured":"Burger JA, Kipps TJ. (2006) CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood. 107:1761\u20137.","journal-title":"Blood"},{"key":"1801019_CR16","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1182\/blood.V96.8.2655","volume":"96","author":"JA Burger","year":"2000","unstructured":"Burger JA, et al. (2000) Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood. 96:2655\u201363.","journal-title":"Blood"},{"key":"1801019_CR17","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1182\/blood.V94.11.3658","volume":"94","author":"JA Burger","year":"1999","unstructured":"Burger JA, Burger M, Kipps TJ. (1999) Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells. Blood. 94:3658\u201367.","journal-title":"Blood"},{"key":"1801019_CR18","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.leukres.2006.11.024","volume":"31","author":"NE Kay","year":"2007","unstructured":"Kay NE, et al. (2007) Bone biopsy derived marrow stromal elements rescue chronic lymphocytic leukemia B-cells from spontaneous and drug induced cell death and facilitates an \u201cangiogenic switch.\u201d Leuk. Res. 31:899\u2013906.","journal-title":"Leuk. Res."},{"key":"1801019_CR19","doi-asserted-by":"publisher","first-page":"3367","DOI":"10.1182\/blood-2009-06-225326","volume":"114","author":"JA Burger","year":"2009","unstructured":"Burger JA, Ghia P, Rosenwald A, Caligaris-Cappio F. (2009) The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood. 114:3367\u201375.","journal-title":"Blood"},{"key":"1801019_CR20","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1111\/j.1582-4934.2009.00697.x","volume":"13","author":"S Gupta","year":"2009","unstructured":"Gupta S, Kass GE, Szegezdi E, Joseph B. (2009) The mitochondrial death pathway: a promising therapeutic target in diseases. J. Cell. Mol. Med. 13:1004\u201333.","journal-title":"J. Cell. Mol. Med."},{"key":"1801019_CR21","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1023\/A:1016119328968","volume":"7","author":"C Soldani","year":"2002","unstructured":"Soldani C, Scovassi AI. (2002) Poly(ADP-ribose) polymerase-1 cleavage during apoptosis: an update. Apoptosis. 7:321\u20138.","journal-title":"Apoptosis"},{"key":"1801019_CR22","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1146\/annurev.immunol.16.1.395","volume":"16","author":"DT Chao","year":"1998","unstructured":"Chao DT, Korsmeyer SJ. (1998) BCL-2 family: regulators of cell death. Annu. Rev. Immunol. 16:395\u2013419.","journal-title":"Annu. Rev. Immunol."},{"key":"1801019_CR23","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1126\/science.278.5345.1966","volume":"278","author":"EH Cheng","year":"1997","unstructured":"Cheng EH, et al. (1997) Conversion of Bcl-2 to a Bax-like death effector by caspases. Science. 278:1966\u20138.","journal-title":"Science"},{"key":"1801019_CR24","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1182\/blood-2007-05-089037","volume":"111","author":"PG Longo","year":"2008","unstructured":"Longo PG, et al. (2008) The Akt\/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells. Blood. 111:846\u201355.","journal-title":"Blood"},{"key":"1801019_CR25","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1677\/erc.0.0080219","volume":"8","author":"JF Lyons","year":"2001","unstructured":"Lyons JF, Wilhelm S, Hibner B, Bollag G. (2001) Discovery of a novel Raf kinase inhibitor. Endocr. Relat. Cancer. 8:219\u201325.","journal-title":"Endocr. Relat. Cancer."},{"key":"1801019_CR26","doi-asserted-by":"publisher","first-page":"3129","DOI":"10.1158\/1535-7163.MCT-08-0013","volume":"7","author":"SM Wilhelm","year":"2008","unstructured":"Wilhelm SM, et al. (2008) Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol. Cancer Ther. 7:3129\u201340.","journal-title":"Mol. Cancer Ther."},{"key":"1801019_CR27","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/S0898-6568(02)00139-0","volume":"15","author":"H Chong","year":"2003","unstructured":"Chong H, Vikis HG, Guan KL. (2003) Mechanisms of regulating the Raf kinase family. Cell. Signal. 15:463\u20139.","journal-title":"Cell. Signal."},{"key":"1801019_CR28","doi-asserted-by":"publisher","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","volume":"64","author":"SM Wilhelm","year":"2004","unstructured":"Wilhelm SM, et al. (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64:7099\u2013109.","journal-title":"Cancer Res."},{"key":"1801019_CR29","doi-asserted-by":"publisher","first-page":"4299","DOI":"10.1073\/pnas.0909299107","volume":"107","author":"EA Murphy","year":"2010","unstructured":"Murphy EA, et al. (2010) Disruption of angiogenesis and tumor growth with an orally active drug that stabilizes the inactive state of PDGFRta\/B-RAF. Proc. Natl. Acad. Sci. U. S. A. 107:4299\u2013304.","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"1801019_CR30","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1182\/blood-2003-08-2763","volume":"104","author":"YK Lee","year":"2004","unstructured":"Lee YK, et al. (2004) VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gallate (EGCG), in B-cell chronic lymphocytic leukemia. Blood. 104:788\u201394.","journal-title":"Blood"},{"key":"1801019_CR31","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1182\/blood-2002-04-1174","volume":"100","author":"IM Pedersen","year":"2002","unstructured":"Pedersen IM, et al. (2002) Protection of CLL B cells by a follicular dendritic cell line is dependent on induction of Mcl-1. Blood. 100:1795\u2013801.","journal-title":"Blood"},{"key":"1801019_CR32","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1182\/blood.V91.7.2387","volume":"91","author":"L Lagneaux","year":"1998","unstructured":"Lagneaux L, Delforge A, Bron D, De Bruyn C, Stryckmans P. (1998) Chronic lymphocytic leukemic B cells but not normal B cells are rescued from apoptosis by contact with normal bone marrow stromal cells. Blood. 91:2387\u201396.","journal-title":"Blood"},{"key":"1801019_CR33","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1634\/theoncologist.12-4-426","volume":"12","author":"D Strumberg","year":"2007","unstructured":"Strumberg D, et al. (2007) Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist. 12:426\u201337.","journal-title":"Oncologist"},{"key":"1801019_CR34","doi-asserted-by":"publisher","first-page":"5472","DOI":"10.1158\/1078-0432.CCR-04-2658","volume":"11","author":"JW Clark","year":"2005","unstructured":"Clark JW, Eder JP, Ryan D, Lathia C, Lenz HJ. (2005) Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin. Cancer Res. 11:5472\u201380.","journal-title":"Clin. Cancer Res."},{"key":"1801019_CR35","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1016\/j.jchromb.2009.04.045","volume":"877","author":"A Haouala","year":"2009","unstructured":"Haouala A, et al. (2009) Therapeutic drug monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 877:1982\u201396.","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"1801019_CR36","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1038\/leu.2011.2","volume":"25","author":"S Huber","year":"2011","unstructured":"Huber S, et al. (2011) Sorafenib induces cell death in chronic lymphocytic leukemia by translational downregulation of Mcl-1. Leukemia. 25:838\u201347.","journal-title":"Leukemia"},{"key":"1801019_CR37","doi-asserted-by":"publisher","first-page":"11851","DOI":"10.1158\/0008-5472.CAN-06-1377","volume":"66","author":"L Liu","year":"2006","unstructured":"Liu L, et al. (2006) Sorafenib blocks the RAF\/MEK\/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC\/PRF\/5. Cancer Res. 66:11851\u20138.","journal-title":"Cancer Res."},{"key":"1801019_CR38","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/BF03402094","volume":"8","author":"E Selzer","year":"2002","unstructured":"Selzer E, et al. (2002) Betulinic acid-induced Mcl-1 expression in human melanoma: mode of action and functional significance. Mol. Med. 8:877\u201384.","journal-title":"Mol. Med."},{"key":"1801019_CR39","doi-asserted-by":"publisher","first-page":"5301","DOI":"10.1038\/sj.onc.1207692","volume":"23","author":"AM Domina","year":"2004","unstructured":"Domina AM, Vrana JA, Gregory MA, Hann SR, Craig RW. (2004) MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol. Oncogene. 23:5301\u201315.","journal-title":"Oncogene"},{"key":"1801019_CR40","first-page":"2178","volume":"60","author":"JM Wood","year":"2000","unstructured":"Wood JM, et al. (2000) PTK787\/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res. 60:2178\u201389.","journal-title":"Cancer Res."},{"key":"1801019_CR41","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/sj.leu.2403667","volume":"19","author":"YK Lee","year":"2005","unstructured":"Lee YK, et al. (2005) VEGF receptors on chronic lymphocytic leukemia (CLL) B cells interact with STAT 1 and 3: implication for apoptosis resistance. Leukemia. 19:513\u201323.","journal-title":"Leukemia"},{"key":"1801019_CR42","doi-asserted-by":"publisher","first-page":"3390","DOI":"10.1158\/1078-0432.CCR-10-0232","volume":"16","author":"J Paesler","year":"2010","unstructured":"Paesler J, et al. (2010) The vascular endothelial growth factor receptor tyrosine kinase inhibitors vatalanib and pazopanib potently induce apoptosis in chronic lymphocytic leukemia cells in vitro and in vivo. Clin. Cancer Res. 16:3390\u20138.","journal-title":"Clin. Cancer Res."}],"container-title":["Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.2119\/molmed.2011.00164.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.2119\/molmed.2011.00164\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.crossref.org\/molmed.2011.00164","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.2119\/molmed.2011.00164.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,2]],"date-time":"2020-07-02T05:54:47Z","timestamp":1593669287000},"score":1,"resource":{"primary":{"URL":"https:\/\/molmed.biomedcentral.com\/articles\/10.2119\/molmed.2011.00164"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,4]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["1801019"],"URL":"https:\/\/doi.org\/10.2119\/molmed.2011.00164","relation":{},"ISSN":["1076-1551","1528-3658"],"issn-type":[{"value":"1076-1551","type":"print"},{"value":"1528-3658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,4]]}}}